HOWL Stock Risk & Deep Value Analysis
Werewolf Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on HOWL
We analyzed Werewolf Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran HOWL through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
HOWL Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About Werewolf Therapeutics Inc (HOWL)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$72.71M
HOWL Deep Value Analysis
HOWL Red Flags & Warning Signs
- âš
Negative or inconclusive clinical trial results for lead programs
- âš
Unexpected safety signals emerging from ongoing studies
- âš
Failure to secure additional funding or significant dilution event
- âš
Competitor product advancements that diminish PREDATORâ„¢'s differentiation
Unlock HOWL Red Flags & Risk Warnings
Create a free account to see the full analysis
HOWL Financial Health Metrics
Market Cap
$72.71M
HOWL Competitive Moat Analysis
Sign in to unlockMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat's durability is largely contingent on the successful clinical development and commercialization of its PREDATORâ„¢-derived therapies, establishing patent protection, and continued innovation that makes the platform difficult to replicate or surpass.
HOWL Competitive Moat Analysis
Sign up to see competitive advantages
HOWL Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q4 2025 Earnings Call (Estimated late February/early March 2026)
- •Updates on ongoing Phase 1/1b clinical trials for lead candidates (e.g., WTX-124, WTX-330)
- •Presentation of preclinical data at scientific conferences
Medium-Term (6-18 months)
- •Initiation of additional cohorts or expansion studies for WTX-124 and WTX-330
- •Potential for new strategic collaborations beyond Bristol Myers Squibb
- •Advancement of preclinical pipeline candidates into IND-enabling studies
Long-Term (18+ months)
- •Pivotal Phase 2/3 trial initiation for a lead candidate
- •Potential for first regulatory submission (e.g., BLA) for a PREDATOR™-derived therapeutic
- •Establishment of PREDATOR™ platform as a leading immuno-oncology modality
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
HOWL Bull Case: What Could Go Right
- ✓
Positive clinical data readouts (Phase 1/2) for WTX-124 and WTX-330
- ✓
Expansion of Bristol Myers Squibb collaboration or new major partnerships
- ✓
Consistent management of cash burn and runway extension through non-dilutive means
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
